Introduction
In vertebrates, the innate immune system provides rapid responses to a wide diversity of microorganisms and orchestrates adaptive immune responses that are specific for individual pathogens. A variety of membrane-associated and cytoplasmic sensors, referred to as pattern recognition receptors (PRRs), bind to microbial products (pathogen-associated molecular patterns, PAMPs) to initiate a diverse set of signaling pathways that restrict growth of the offending organism. Antiviral responses are typically marked by induction of type I interferon (IFN) through sensors that recognize viral nucleic acids. These responses inhibit viral replication by myriad mechanisms and also enhance the ability of antigen-presenting cells to prime the adaptive immune system, promoting viral clearance and immunological memory. In turn, viruses have evolved multiple means of circumventing innate defense mechanisms, ensuring their survival and transmission.
HIV-1 and other retroviruses are unusual as they do not appear to directly alert host innate defenses to their presence, and HIV-1 does not seem to induce IFN in its major target cells, the CD4 + T lymphocytes. However, HIV-infected individuals often suffer not only from immunodeficiency characterized by progressive loss of CD4 + T cells but also from generalized immune activation, with elevated cytokine and immunoglobulin levels. The high level of circulating type I IFN in AIDS patients is therefore often considered to be due to an innate antiviral response, but the absence of IFN secretion by infected cells suggests that it is an indirect consequence of infection. Early after infection, extensive viral replication and T cell loss are most apparent in the intestinal lamina propria, where cells of the immune system regulate the balance of the commensal microbiota and the integrity of the mucosal epithelial barrier. AIDS-associated immune activation has been proposed to be a consequence of a breakdown of the mucosal barrier and the leakage of bacterial products into the circulation (Brenchley et al., 2006) . The elevated levels of type I IFN may thus reflect failure of barrier function, opportunistic infections, or changes in the composition of the intestinal microbiota. Uptake of debris from HIV-infected T cells by plasmacytoid dendritic cells (pDCs) may also activate innate signaling and production of type I IFN by these specialized cells (Lepelley et al., 2011) . Due to timing and proximity, these indirect mechanisms for induction of type I IFN may not be effective in limiting replication of HIV-1, which is highly sensitive to IFN, and may not contribute effectively to enhancing antiviral adaptive immunity. The failure of the virus to be directly recognized by the innate immune system may thus underlie, at least in part, the difficulty in generating sterilizing immune responses in infected individuals and the failures, thus far, of HIV vaccine trials. The absence of IFN induction upon infection with HIV-1 may reflect a virulence strategy of the virus. It is also possible that retroviral replication intermediates may be subject to processes that have evolved to prevent potentially detrimental activation of innate immune sensors by nucleic acid byproducts generated in the course of normal cell growth. Indeed, several studies published during the past year indicate that mammalian cells have mechanisms for responding to HIV-1 through activation of innate sensors, but such responses are minimized by virus-specific and general host physiological processes (Doitsh et al., 2010; Lepelley et al., 2011; Yan and Lieberman, 2011) . Here we review some of the recent advances (Hrecka et al., 2011; Laguette et al., 2011) in our understanding of innate responses to infection with HIV-1 and related lentiviruses and discuss these in the context of host protection and vaccine strategy.
Aicardi-Goutiè res Syndrome Genes in Restriction of HIV-1 Replication and Innate Sensing Type I IFN is tightly regulated to ensure rapid antimicrobial responses while avoiding potential damage to the host. A spectrum of human inflammatory diseases with manifestations resembling chronic viral infection, including Aicardi-Goutiè res Syndrome (AGS) and familial chilblain lupus, have been associated with unchecked production of type I IFN. The best characterized genetic defects in AGS patients affect the activity of TREX1, a 3 0 to 5 0 exonuclease whose absence leads to accumulation of cytoplasmic single-stranded DNA (ssDNA). Such misplaced excess DNA, which may be derived from excision-mediated DNA repair or retrotransposition (Stetson et al., 2008) , is thought to activate a thus far unidentified cytoplasmic DNA sensor(s) (Barber, 2011) . Recently, Yan et al. (2010) found that inactivation of TREX1 in a variety of cell types infected with HIV-1 resulted in enhanced expression of type I IFN. In the absence of TREX1, HIV infection was sensed by a mechanism that required the signaling molecules STING, TBK1, and IRF3, all of which had been previously implicated in activation of IFN expression in response to viral infections. IFN production was blocked by a reverse-transcriptase inhibitor, indicating a requirement for conversion of viral RNA into DNA, but it was not affected by integrase inhibition, indicating that insertion of the provirus in the target cell genome and expression of additional viral products were not required. Furthermore, the absence of TREX1 potentiated sensing of ssDNA hybrid molecules and had a less pronounced effect on ssRNA, RNA:DNA, or doublestranded DNA (dsDNA) sensing. Thus, an ssDNA intermediate that occurs during HIV-1 reverse transcription, after first-strand synthesis, likely constitutes the analog substrate sensed in cells defective for TREX1 ( Figure 1A ).
TREX1 mutations account for a large proportion of AGS patients, but mutations in SAMHD1, RNASEH2A, RNASEH2B, and RNASEH2C also result in AGS and related diseases. All of these molecules are thought to also have enzymatic activities that regulate nucleic acid catabolism. Two recent studies have shown that SAMHD1 additionally has an important role in restricting the replication of HIV-1 in cells of the myeloid lineage (Hrecka et al., 2011; Laguette et al., 2011) . HIV-1 and the related primate and SIVmac express the accessory protein Vpx, which is encapsidated within viral particles. When the virus fuses with the target cells, Vpx is physically delivered within the target cell cytosol along with the viral core. Vpx bridges a ubiquitin ligase complex containing at least CUL4, DDB1, and DCAF1 to SAMHD1, leading to its proteasome-dependent degradation. In the absence of SAMHD1, reverse transcription is no longer restricted and viral cDNA (dsDNA) is synthesized and integrated.
lentiviruses HIV-2 and SIV infect cells that express CD4 and an appropriate chemokine receptor, usually CCR5 and occasionally CXCR4 or other receptors. This receptor restriction limits the host range of viral entry to T helper cells and myeloid cells, including macrophages and dendritic cells (DCs). However, the magnitude of infection with HIV-1 is cell type specific. Human peripheral CD4 + T cells are more susceptible to infection with HIV-1 than macrophages or DCs. DCs are poorly infected in culture, and it remains unclear to what extent they are infected in patients. Despite their relative resistance to infection with HIV-1, DCs have a unique capacity to take up intact viral particles and hand them off to susceptible T cells, thus enhancing T cell infection in trans. This phenomenon of trans-enhancement highlights the ability of HIV-1 to potentially exploit the cellular trafficking machinery of DCs while avoiding activation of the innate immune recognition pathways in these cells (Izquierdo-Useros et al., 2010) .
The presence of a myeloid-specific factor(s) that restricts HIV-1 infection was originally suggested by studies aimed at characterizing the potency of retroviral vectors in mediating gene transduction, for use in gene therapy (Mangeot et al., 2002) . Later studies demonstrated that a myeloid cell-specific dominant restriction factor limits the extent of reverse transcription following viral entry. The restriction also limited infection with HIV-2 and SIVmac if these viruses were defective for the accessory protein Vpx, which is not encoded by HIV-1. Remarkably, Vpx delivery by virus-like particles (VLPs) could alleviate the block to infection of monocyte-derived dendritic cells (MDDC) with HIV-1 (Goujon et al., 2006) . Along with a series of biochemical studies that implicated Vpx in recruiting an E3 ubiquitin ligase, this finding suggested that Vpx mediates degradation of the myeloid restriction factor. Laguette et al. and Hrecka et al. (Hrecka et al., 2011; Laguette et al., 2011) have now identified SAMHD1 as the restriction factor expressed in myeloid cells and targeted by Vpx ( Figure 1B) .
Laguette et al. used epitope-tagged Vpx expressed in differentiated THP-1 monocytic cells to identify SAMHD1. Hrecka et al. employed an approach based on their earlier demonstration of a requirement for the DCAF1 substrate receptor and the DDB1-CUL4 E3 ubiquitin ligase complex to mediate Vpx function in primary macrophages (Srivastava et al., 2008) . Using epitopetagged CUL4 and Vpx expressed in HEK293T cells, they showed Vpx-dependent copurification of SAMHD1. Exposure of differentiated THP-1 cells or monocyte-derived macrophages to Vpx-containing SIVmac virus-like particles led to proteasomedependent degradation of SAMHD1. Finally, overexpression and RNAi approaches showed that SAMHD1 is required in differentiated THP-1 cells, macrophages, and MDDC for restriction to infection with HIV-1.
It remains unclear why SAMHD1 restricts infection of myeloid cells but not other cells with HIV-1. Biochemical association of Vpx with SAMHD1 was observed in nonmyeloid cell lines that can be readily infected without the need for Vpx. Intriguingly, the restriction does not occur in SAMHD1-expressing THP-1 cells when they are cycling but requires differentiation-induced cell-cycle arrest. This observation suggests that the restriction may apply to a broader category of noncycling cells, such as resting CD4 + T lymphocytes. It is possible that, in cycling cells, SAMHD1 is directed toward sites for degrading host nucleic acids generated during DNA replication and thus spares the incoming viral genome. Although the precise function of SAMHD1 is not known, molecules with similar sequence have been shown to have nucleoside phosphohydrolase activity (Aravind and Koonin, 1998) . Like TREX1, SAMHD1 may thus assist in restraining aberrant activation of innate immune sensors by eliminating excess or misplaced nucleic acids, and the same enzymatic activity may also prevent synthesis of the retroviral cDNA.
Sensing of HIV-1 by Dendritic Cells Does SAMHD1, like TREX1, limit sensing of HIV-1 nucleic acid by the host innate immune system? A separate line of inquiry into DC innate responses to HIV-1 suggests that this may be so. Unexpectedly, when the restriction to HIV-1 replication in MDDC was relieved by delivery of Vpx, there was potent activation of an innate response marked by expression of IFN-b and upregulation of cell-surface CD80 and CD86, which provide costimulatory function for activation of T cells (Manel et al., 2010) . This response required the interaction between de novo synthesized viral capsid protein (embedded in the Gag precursor) and cellular cyclophilin A (CypA), a peptidylprolyl isomerase, leading to phosphorylation of IRF3. Multiple lines of evidence indicated that viral components that accumulate prior to integration (e.g., incoming capsid protein and viral nucleic acids) were unable to activate DCs (Manel et al., 2010; Sunseri et al., 2011) . Unlike the case of TREX1-deficient cells, this suggests that accumulation of incoming viral RNA and reverse-transcribed DNA is not sufficient to activate DCs. Because this response required the activity of Vpx, which is absent in HIV-1, most likely through degradation of SAMHD1, it was termed ''cryptic.'' What is the PAMP of HIV-1 sensed in the absence of SAMHD1? The contribution of capsid to sensing of HIV-1 satisfies a functional definition for a PAMP, but whether capsid itself is the physical substrate of sensing is not known. In HIV capsid, the amino acids required for innate sensing map to a known domain of the protein that binds to CypA. The interaction with CypA induces a conformational change in capsid, which modulates the efficiency and kinetics of viral uncoating-an intracellular process leading to release of viral nucleic acid in the target cell. More recent evidence suggests that interaction of capsid with cellular factors also modulates a later stage in the viral life cycle, namely the integration of the viral cDNA in the target cell genome (Ocwieja et al., 2011) . These properties suggest that capsid could regulate the availability of the viral nucleic acid to cytoplasmic sensors. They also suggest that incoming viral capsid can have different fates, or routes, that may influence the mechanism of infection and, hence, the mode of innate sensing.
The discovery of SAMHD1 as the target of Vpx-induced degradation raises the possibility that a viral nucleic acid that is normally targeted by SAMHD1 serves the role of a PAMP upon infection of myeloid cells with HIV-1. On this basis, we can propose three models of cyclophilin-dependent sensing of HIV, depending on the physical PAMP ( Figure S1 available online). In the first model, capsid is the physical PAMP that directly leads to innate activation through interaction with CypA and an appropriate sensor. Because DC activation was not observed when incoming capsid alone was present in cells, a specific feature of newly synthesized capsid, such as subcellular trafficking, leads to sensing. In a second model, a viral nucleic acid is the physical PAMP. To release this PAMP, CypA recruitment when capsid is newly made would affect remaining incoming viral cores, leading to activation of an innate sensor(s). In a third model, the PAMP is unknown. CypA complexed to or enabled by newly synthesized capsid acts as a chaperone for the sensor, facilitating its interaction with the unknown PAMP, which could be any molecule, such as nucleic acids normally targeted by TREX1 or SAMHD1. The last two models would, potentially, permit sensing of intact nucleic acid (e.g., reverse-transcribed ssDNA) even in the presence of TREX1. We do not know, however, whether TREX1 activity requires SAMHD1. Alternatively, a subset viral ssDNA may be protected from TREX1-mediated degradation by the capsid-CypA complex. Vpx-mediated degradation of SAMHD1 in DCs and macrophages would then prevent degradation of nucleic acids that activate a sensor. Intriguingly, type I IFN induction is generally not observed in T cells or other nonmyeloid cells infected productively with HIV, regardless of whether Vpx is present. This suggests the existence of myeloid-specific properties of the viral PAMP, TREX1, SAMHD1, or the sensor.
A major goal now is to identify one or more sensors involved in activation of the type I IFN response in infected cells. It is likely that a sensor for DNA has an important role not only in mediating the response to lentivirus infection but also in promoting inflammation in AGS and related lupus-like diseases.
Coupling of HIV Innate Sensing with Adaptive Immunity
The recent findings outlined above suggest that, by unleashing the intrinsic capacity of HIV-1 to activate innate immune sensors, it may be possible to better control and prevent infection. Early mucosal production of type I IFN by resident sentinel cells would effectively limit or delay replication in infected CD4 (Pulendran and Ahmed, 2011) . Although there has been little comparison between wild-type viruses and the related attenuated vaccine strains for innate responses that they elicit, it is likely that the effectiveness of the live attenuated vaccines is at least in part due to activation of host responses that have evolved to deal most effectively with that pathogen. In line with this argument, an effective host response against primate lentiviruses may have evolved but may not be engaged upon infection with HIV-1 due to activity of enzymes such as TREX1 and SAMHD1. HIV-2, a lentivirus that can overcome the host restriction through expression of Vpx, can productively infect and activate DCs (Manel et al., 2010) . It is noteworthy that individuals infected with HIV-2 appear to have a better outcome than those infected with HIV-1. It will be important to determine whether the control of infection in these patients is due to induction of Vpx-dependent innate and adaptive immune responses. Insight into mechanisms of viral control may also come from studies of cohorts of ''elite controllers,'' whose immune defenses effectively restrict viral replication (Sá ez-Cirió n et al., 2011). It is possible that at least some elite controllers have enhanced innate responses upon infection or may be able to restrict HIV-1 replication in T cells through mechanisms similar to those in myeloid cells.
Implications of HIV-1 Sensing for Control of Infection and for Vaccine Development
An immune response to HIV-1 occurs in pathogenic infection but is not generally protective, partly because it fuels viral replication and contributes to inflammation. As DCs express SAMHD1, a cell-autonomous innate response to the virus is restrained. The immune response to HIV-1 may compensate inefficiently for the absence of this innate response, leading to immunopathology (Nish and Medzhitov, 2011) . Activation of the cryptic innate immune pathway may help to control viral replication, for instance through antiviral effects of IFN and improved priming of HIVspecific T cells by DC, which would reduce the burden of control and the pool of activated CD4 + T cells available for infection.
The recent discoveries suggest that it may be possible to harness the innate immune response to HIV-1 for therapeutic and prophylactic vaccination. For example, strategies aimed at inhibiting SAMHD1 activity, allowing infection and activation of DC, could potentially enhance the quality and quantity of virusspecific adaptive immunity. In this context, it will be important to understand the impact of innate immune activation on host protection in patients infected with HIV-2 and in SIV-infected nonhuman primates. Approaches that incorporate HIV-specific activation of innate immunity may therefore be important for future design of HIV therapies and vaccines.
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